Landec shareholders approve amendment to 2019 Stock Incentive Plan increasing share reserve by 759,797 shares

LIFECORE BIOMEDICAL, INC. DE

Shareholders elected Katrina L. Houde, Nelson Obus, and Jeffrey L. Edwards to the board with votes ranging from 15.2M to 17.7M for each.
Amendment increases share reserve from 2,000,000 to 2,759,797 shares (759,797 new shares) and increases ISO limit to same total.
Non-employee director annual award limit increased from $120,000 to $350,000 per fiscal year.
Ratified Ernst & Young as independent auditor for fiscal year ending May 28, 2023 with 24.2M for, 9k against.
Advisory vote on named executive officer compensation approved: 20.2M for, 1.1M against, 324k abstain.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LIFECORE BIOMEDICAL, INC. DE shareholders approved Approval of amendment to the Landec Corporation 2019 Stock Incentive Plan.

Proposal: equity plan
Outcome: passed

Exact text from the filing

Stockholders approved the amendment to the Landec Corporation 2019 Stock Incentive Plan, with votes as follows: For Against Abstain Broker Non-Votes 18,487,481 3,096,263 16,615 2,698,258

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LIFECORE BIOMEDICAL, INC. DE shareholders approved Approval of non-binding advisory proposal on the executive compensation of the Company's named executive officers.

Proposal: say on pay
Outcome: passed

Exact text from the filing

Stockholders approved the compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with votes as follows: For Against Abstain Broker Non-Votes 20,189,411 1,086,858 324,090 2,698,258

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LIFECORE BIOMEDICAL, INC. DE shareholders approved Election of three directors for a two-year term.

Proposal: director election
Outcome: passed

Exact text from the filing

The voting results for the election of directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Katrina L. Houde 15,180,997 6,419,362 2,698,258 Nelson Obus 17,689,049 3,911,310 2,698,258 Jeffrey L. Edwards 17,743,088 3,857,271 2,698,258

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LIFECORE BIOMEDICAL, INC. DE shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending May 28, 2023 at the 2023-05-28 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-28

Exact text from the filing

Stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending May 28, 2023, with votes as follows: For Against Abstain 24,245,636 8,975 44,006

View on SEC.gov

352 shareholder votes filed in the last 30 days. Browse all shareholder votes →

LIFECORE BIOMEDICAL, INC. DE filing history →

Source: SEC EDGAR

accession 0001005286-22-000065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.